GET DAILY SIGNALSAstraZeneca (AZN) +100% Run: Can the Shares Reach the $208 Analyst Target?
Key Takeaways
- The central $208 target is the rounded average of published 12-month analyst price targets, which sit near $206–$208 across major providers.
- At a recent price near $185, hitting $208 would mean roughly 12% upside—a measured but meaningful step.
- Analyst targets span a broad range from about $158 to $259, highlighting differing views on valuation and pipeline delivery.
- Most firms rate the stock a Buy; nine of ten raised targets after the third-quarter results, though a few Hold-rated views sit below the current price.
- Support stems from oncology growth, a reaffirmed 2026 outlook, and an $80 billion 2030 revenue goal; risks include a premium valuation and recent pipeline misses.
- Track updates via dedicated pages for Major News, Today's Price Move, a longer-term Forecast, and upcoming Earnings.
Analyst Price Targets and Consensus View
The $208 central target represents the average of verified analyst estimates. Yahoo Finance shows a one-year target of $208.07, S&P Global’s poll of 12 analysts comes in at $208.08, and MarketBeat’s sample of 19 analysts reports $206.67. These figures align closely enough that rounding to $208 gives a solid consensus reading.
Dispersion remains wide, however. Targets range from roughly $158 on the cautious side to around $259 at the bullish end, with most falling between $200 and $240. That spread captures real differences in how analysts weigh the premium valuation, oncology momentum, and mixed pipeline results in 2026.
Overall sentiment stays constructive. After the third-quarter report, nine of ten houses lifted their targets, while Deutsche Bank stands out with a Hold rating and a target below the current price. Bullish voices such as Bernstein and Citi point to underappreciated growth outside oncology and strong pipeline potential.
Current Market Position and Path Toward the Target
Trading near $185—inside a 52-week range of $153.41 to $212.71—the $208 target calls for about a 12% advance. That feels modest next to the stock’s recent volatility and its more-than-doubling over the past year.
Fundamentals offer a plausible base. Third-quarter revenue climbed 7% to $16.21 billion, core EPS rose 17% to $2.79, and oncology revenue grew 17% to $7.77 billion. Management kept 2026 guidance steady for mid-to-high single-digit revenue growth and low-double-digit core EPS growth at constant currency, while signaling a dividend increase to $3.30 per share. Even so, with a trailing P/E near 26, reaching $208 hinges more on execution than on multiple expansion.
Factors That Could Support a Move Toward the Target
- Oncology momentum: Tagrisso, Imfinzi, and Enhertu (recently approved in the European Union) continue to drive double-digit growth in the largest therapeutic area.
- Guidance and ambition: The reaffirmed 2026 outlook and the $80 billion 2030 revenue target provide analysts with a clear long-term framework.
- Portfolio expansion: A reported ~$10 billion bid for obesity-focused Rhythm Pharmaceuticals and the acquisition of vaccine developer Omniose point to interest in new growth areas.
- Cost discipline: A restructuring program targeting $1.5 billion in annualized pre-tax savings aims to fund R&D while protecting margins.
- Analyst revisions: The pattern of post-earnings target increases signals rising conviction, which has historically aided upward moves.
Factors That Could Keep the Target Out of Reach
- Valuation: At roughly 26 times trailing earnings, the shares already embed significant growth expectations, leaving little margin for shortfalls.
- Pipeline setbacks: The discontinuation of the volrustomig lung cancer trial (eVOLVE-Lung02) and the SERENA-4 miss in breast cancer highlight clinical execution risk.
- Rising costs: Fourth-quarter R&D spending and a one-time charge tied to the Summit equity investment could weigh on near-term results.
- Regulatory and pricing pressure: Ongoing U.S. drug-pricing efforts remain a sector-wide concern.
- Macro sensitivity: Even defensive healthcare names can face rotation and rate-driven pressure, as seen in recent pullbacks.
Technical Levels and Market Structure
The long-term uptrend holds, yet the $212.71 area—the 52-week high—remains the critical overhead resistance. A decisive break above that zone would bring the $208 target and higher analyst objectives into clearer view. Support has formed in the mid-$160s to low-$170s, a region the shares tested before the post-earnings rally. The wide distance between support and resistance shows how quickly sentiment can shift.
Time Horizon and What Investors Should Monitor
Analyst targets typically cover a roughly 12-month horizon, so the $208 level should be viewed in that context rather than as a short-term call. Key items to watch include the next quarterly results and any updates to 2026 guidance, the outcome of the Rhythm Pharmaceuticals bid, additional pipeline readouts, and interest-rate or sector-rotation effects that could compress pharma multiples. Revisions from analysts will serve as an early indicator of how views on the $208 level are evolving.
I also checked comparable names using Tickeron’s AI Screener to see how AZN stacks up within the sector.
AI Daily Buy/Sell Signals
Tickeron's AI Daily Buy/Sell Signals apply artificial intelligence to scan thousands of stocks and ETFs, producing Buy, Sell, or Hold signals as conditions, technical patterns, and model-driven analysis change. I find these signals helpful for spotting fresh ideas, reviewing current holdings, and identifying trend shifts more efficiently than manual reviews alone. For names like AstraZeneca, the service adds a systematic layer to fundamental work. I’m watching how the model currently interprets market conditions for this stock.
Final Assessment
Whether AstraZeneca can reach $208 is not a straightforward yes-or-no question. The central target—derived from the average of published analyst estimates—sits roughly 12% above the current price, a modest gap relative to the recent advance. Strong oncology performance, steady guidance, and a wave of post-earnings target increases support the case, while a rich valuation, recent clinical disappointments, and the spread between bullish and cautious targets call for measured expectations. Reaching $208 remains well within the range analysts are discussing, yet success will depend on continued earnings beats and the next developments in the pipeline and M&A activity rather than valuation expansion alone.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
AZ in upward trend: price rose above 50-day moving average on November 06, 2026
AZ moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend. In 38 of 46 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The 10-day moving average for AZ crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 82%.
Following a +11.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where AZ advanced for three days, in 206 of 254 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 46 of 51 cases where AZ's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AZ as a result. In 84 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AZ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
AZ broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for AZ entered a downward trend on October 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 44 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.170) is normal, around the industry mean (-1.906). P/E Ratio (-7.488) is within average values for comparable stocks, (9.554). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.824). Dividend Yield (0.000) settles around the average of (0.069) among similar stocks. P/S Ratio (16.313) is also within normal values, averaging (70.383).
The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating steady price growth. AZ’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 59 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AZ’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry PackagedSoftware
Advertisement